Health ❯ Healthcare ❯ Pharmaceuticals

FDA Approvals

Leucovorin Calcium PADCEV and Keytruda Clinical Trials Adaptimmune New Medical Products Cell Therapy Diabetes Treatments

Exa‑cel Posts Complete Primary-End Point Responses in Early Pediatric Trials, With One Fatal Busulfan Event

Early ASH data point to strong efficacy in 5–11-year-olds using a CRISPR-edited autologous transplant that requires risky busulfan conditioning.

FDA Clears Padcev Plus Keytruda Regimens as Perioperative Option for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

FDA Reapproves GSK’s Blenrep for Multiple Myeloma in Narrow Combination Use